title: Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.
abstract: Interleukin-2-based regimens of biological therapy have shown some clinical promise for the treatment of kidney cancer in humans, although the mechanisms responsible for tumor regression occurring in these patients remain unclear. Preclinical insight into these mechanisms is limited by a paucity of orthotopic animal models of kidney cancer. We have used streptozotocin, an antibiotic and diabetogenic nitrosamine compound derived from Streptomyces achromogenes to induce new kidney tumors in BALB/c mice. Single or multiple doses of streptozotocin induced kidney tumors in up to 25% of mice by 50-90 weeks of age, with up to 18% characterized as renal cell carcinomas (RCCs). Several transplantable lines were obtained from the RCCs, and one of these lines was subsequently cloned. The initial tumor isolates and sublines were histologically reconfirmed to be RCCs, and all grew progressively but slowly (mean survival times, 57 to >100 days) in vivo after intrarenal implant. None of the primary isolates or sublines revealed mutations in either the VHL or Ras genes, although karyotype analysis and chromosome painting revealed the consistent presence of a submetacentric chromosome resulting from the fusion of chromosomes 16 and 19. Biological characterization of these tumors revealed several features analogous to the growth of human kidney cancers, including a propensity for the formation of lung metastases and high vascularity. This hypervascularity is evident by both gross and microscopic analysis and correlates with the expression of several proangiogenic genes. Overall, the features of orthotopic transplantability, slower in vivo growth (relative to the rapid growth rates of other transplantable mouse kidney tumors), propensity for lung metastases, and hypervascularity may make these tumors valuable models for the study of new therapeutic strategies based on antineovascular agents and antitumor cytokines.
authors.affiliation: Laboratories of Experimental Immunology, Center for Cancer Research, IRSP, Frederick, Maryland, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Gruys
authors.forename: T C
authors.initials: TC
authors.lastname: Back
authors.forename: J
authors.initials: J
authors.lastname: Subleski
authors.forename: T A
authors.initials: TA
authors.lastname: Wiltrout
authors.forename: J K
authors.initials: JK
authors.lastname: Lee
authors.forename: L
authors.initials: L
authors.lastname: Schmidt
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: R
authors.initials: R
authors.lastname: Stanyon
authors.forename: J M
authors.initials: JM
authors.lastname: Ward
authors.forename: J M
authors.initials: JM
authors.lastname: Wigginton
authors.forename: R H
authors.initials: RH
authors.lastname: Wiltrout
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003546:Cysteine Endopeptidases; D004252:DNA Mutational Analysis; D005260:Female; D007680:Kidney Neoplasms / Q000098:blood supply / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000235:genetics; D013311:Streptozocin
chemical_list: D009363:Neoplasm Proteins; D013311:Streptozocin; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant